JP2020502056A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502056A5 JP2020502056A5 JP2019524445A JP2019524445A JP2020502056A5 JP 2020502056 A5 JP2020502056 A5 JP 2020502056A5 JP 2019524445 A JP2019524445 A JP 2019524445A JP 2019524445 A JP2019524445 A JP 2019524445A JP 2020502056 A5 JP2020502056 A5 JP 2020502056A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- preparation
- preparation according
- rps2
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 201000001421 hyperglycemia Diseases 0.000 claims description 3
- 230000036772 blood pressure Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 102000004339 Ribosomal protein S2 Human genes 0.000 claims 4
- 108090000904 Ribosomal protein S2 Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 239000006172 buffering agent Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102100037563 40S ribosomal protein S2 Human genes 0.000 claims 1
- 101710107640 40S ribosomal protein S2 Proteins 0.000 claims 1
- 102400000321 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical group P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
- 229960004666 glucagon Drugs 0.000 claims 1
- 230000009229 glucose formation Effects 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000002953 phosphate buffered saline Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023016485A JP7711967B2 (ja) | 2016-11-13 | 2023-02-07 | 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法 |
| JP2025113059A JP2025163025A (ja) | 2016-11-13 | 2025-07-03 | 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662421332P | 2016-11-13 | 2016-11-13 | |
| US62/421,332 | 2016-11-13 | ||
| PCT/US2017/061343 WO2018089909A1 (en) | 2016-11-13 | 2017-11-13 | Compositions and methods for treating diabetes, hypertension and hypercholesterolemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023016485A Division JP7711967B2 (ja) | 2016-11-13 | 2023-02-07 | 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020502056A JP2020502056A (ja) | 2020-01-23 |
| JP2020502056A5 true JP2020502056A5 (enExample) | 2021-01-07 |
Family
ID=62107069
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524445A Pending JP2020502056A (ja) | 2016-11-13 | 2017-11-13 | 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法 |
| JP2023016485A Active JP7711967B2 (ja) | 2016-11-13 | 2023-02-07 | 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法 |
| JP2025113059A Pending JP2025163025A (ja) | 2016-11-13 | 2025-07-03 | 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023016485A Active JP7711967B2 (ja) | 2016-11-13 | 2023-02-07 | 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法 |
| JP2025113059A Pending JP2025163025A (ja) | 2016-11-13 | 2025-07-03 | 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10548941B2 (enExample) |
| EP (1) | EP3538124A4 (enExample) |
| JP (3) | JP2020502056A (enExample) |
| KR (1) | KR102497242B1 (enExample) |
| CN (1) | CN110087666B (enExample) |
| AU (2) | AU2017357052B2 (enExample) |
| BR (1) | BR112019009511A2 (enExample) |
| CA (1) | CA3041362A1 (enExample) |
| MX (1) | MX2019005466A (enExample) |
| WO (1) | WO2018089909A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3041362A1 (en) * | 2016-11-13 | 2018-05-17 | Imagine Pharma, Llc | Compositions and methods for treating diabetes, hypertension and hypercholesterolemia |
| CN112423772A (zh) * | 2018-01-09 | 2021-02-26 | 想象制药有限责任公司 | Rps2肽调节内皮细胞功能障碍的用途 |
| KR20210024557A (ko) * | 2018-06-25 | 2021-03-05 | 이매진 파마 | 인슐린 생산용 소도 세포를 확산시키기 위한 조성물 및 방법 및 이의 치료적 용도 |
| CN110974943A (zh) * | 2019-12-09 | 2020-04-10 | 广东药科大学 | 一种口服胰岛素药物制剂及其制备方法 |
| IL311468A (en) * | 2021-09-22 | 2024-05-01 | Imagine Pharma Llc | Compositions and methods for the proliferation of insulin- and glucagon-secreting cells from type 1 diabetic pancreatic tissue and their therapeutic uses |
| JP2024545981A (ja) * | 2021-12-11 | 2024-12-17 | イマジン ファーマ、エルエルシー | 経口投与のための組成物および方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4025395B2 (ja) * | 1997-04-09 | 2007-12-19 | 花王株式会社 | 新規ペクチン酸リアーゼ |
| US20020042062A1 (en) * | 1999-09-24 | 2002-04-11 | Mark Stearns | Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| AUPR311601A0 (en) | 2001-02-15 | 2001-03-08 | Adp Pharmaceutical Pty Limited | Matrix gene expression in chondrogenesis |
| US20050118151A1 (en) * | 2001-05-29 | 2005-06-02 | Syddansk Universitet | Proteins in diabetes proteome anlysis |
| AU2002365904A1 (en) * | 2001-07-10 | 2003-09-04 | Gene Logic, Inc. | Cardiotoxin molecular toxicology modeling |
| EP1490104B1 (en) * | 2002-04-02 | 2012-06-06 | Ben-Gurion University Of The Negev Research And Development Authority | Protein-based streptococcus pneumoniae vaccines |
| AU2004251654A1 (en) * | 2003-06-02 | 2005-01-06 | Icoria, Inc. | Use of genes differentially expressed during aging of liver for treatment and diagnosis |
| JP2005245202A (ja) * | 2004-03-01 | 2005-09-15 | Japan Science & Technology Agency | ヒトＴＦＩＩＥαの新規な亜鉛結合ドメインの構造的特徴および機能 |
| US20090048199A1 (en) * | 2007-03-09 | 2009-02-19 | Hiberna Corporation | Hibernation-Related Genes and Proteins, Activators and Inhibitors Thereof and Methods of Use |
| JP2012525146A (ja) * | 2009-04-28 | 2012-10-22 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 細胞透過のための過剰に荷電されたタンパク質 |
| US20140080824A1 (en) | 2010-10-21 | 2014-03-20 | New York University | Structure-guided identification of binding interactions of human laminin receptor precursor with laminin and identification of compounds that affect binding |
| WO2012065178A2 (en) | 2010-11-12 | 2012-05-18 | The Johns Hopkins University | Albumin-bound protein/peptide complex as a biomarker for disease |
| SI2681227T1 (sl) | 2011-03-01 | 2016-04-29 | Nucana Biomed Limited | Fosforamidatni derivati 5-fluoro-2'-deoksiuridina za uporabo pri zdravljenju raka |
| WO2015048334A2 (en) * | 2013-09-25 | 2015-04-02 | Pronutria, Inc. | Edible species nutritive polypeptides and methods of production and use thereof |
| ES2799503T3 (es) | 2014-10-31 | 2020-12-18 | Ngm Biopharmaceuticals Inc | Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos |
| WO2017109706A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| CA3041362A1 (en) * | 2016-11-13 | 2018-05-17 | Imagine Pharma, Llc | Compositions and methods for treating diabetes, hypertension and hypercholesterolemia |
| CN112423772A (zh) * | 2018-01-09 | 2021-02-26 | 想象制药有限责任公司 | Rps2肽调节内皮细胞功能障碍的用途 |
-
2017
- 2017-11-13 CA CA3041362A patent/CA3041362A1/en active Pending
- 2017-11-13 EP EP17868911.3A patent/EP3538124A4/en active Pending
- 2017-11-13 AU AU2017357052A patent/AU2017357052B2/en active Active
- 2017-11-13 KR KR1020197015784A patent/KR102497242B1/ko active Active
- 2017-11-13 US US15/811,060 patent/US10548941B2/en active Active
- 2017-11-13 JP JP2019524445A patent/JP2020502056A/ja active Pending
- 2017-11-13 CN CN201780069543.0A patent/CN110087666B/zh active Active
- 2017-11-13 MX MX2019005466A patent/MX2019005466A/es unknown
- 2017-11-13 WO PCT/US2017/061343 patent/WO2018089909A1/en not_active Ceased
- 2017-11-13 BR BR112019009511-0A patent/BR112019009511A2/pt active Search and Examination
-
2019
- 2019-06-28 US US16/455,878 patent/US10751384B2/en active Active
-
2022
- 2022-05-31 AU AU2022203741A patent/AU2022203741B2/en active Active
-
2023
- 2023-02-07 JP JP2023016485A patent/JP7711967B2/ja active Active
-
2025
- 2025-07-03 JP JP2025113059A patent/JP2025163025A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502056A5 (enExample) | ||
| Ibraheem et al. | Administration strategies for proteins and peptides | |
| US20220054594A1 (en) | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 | |
| RU2471867C2 (ru) | Гиалуронидаза и способ ее применения | |
| JP5964373B2 (ja) | 糖尿病および他の慢性疾患の治療に有用な組成物 | |
| CN115916772A (zh) | 6-氧代-3,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用 | |
| JP2014526441A5 (enExample) | ||
| ES2723887T3 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| CN101912600B (zh) | 改善胰岛素在溶液中稳定性的方法 | |
| JP2011001381A (ja) | Ｇｌｐ−１医薬組成物 | |
| JP2011512856A5 (enExample) | ||
| ATE332138T1 (de) | Flibanserin zur behandlung extrapyramidaler bewegungsstörungen | |
| EP3268029B1 (en) | Treatment of type 2 diabetes mellitus patients | |
| JP2015504073A5 (enExample) | ||
| JP2020535161A5 (enExample) | ||
| JP2009544585A5 (enExample) | ||
| RU2012136530A (ru) | Новые соединения, влияющие на пищевое поведение | |
| BRPI0607097B8 (pt) | uso de um peptídeo imunogênico para a fabricação de um medicamento para o tratamento, prevenção ou redução de infecção por papilomavírus | |
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| CN110087666A (zh) | 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法 | |
| JP2009500045A5 (enExample) | ||
| CN115697385A (zh) | 一种治疗脊髓性肌萎缩症的方法和药物 | |
| BR112019026336A2 (pt) | forma de sal de cloridrato de um peptídeo análogo da porção c-terminal de c5a e o uso da mesma, composição, método para induzir uma resposta imune contra uma infecção ou câncer, kit e composto para aumentar uma resposta imune para um agente imunogênico | |
| CA2755897A1 (en) | Treatment of cancers with immunostimulatory hiv tat derivative polypeptides | |
| JP2015524808A5 (enExample) |